Krish | Immunology, T Cells, Cancer & Mutations | Stadtman Investigator @theNCI @NCI_CCR_SB | Views don't represent NIH, NCI or HHS | 🇮🇳🇺🇸
Dec 11, 2020 • 11 tweets • 5 min read
With @franklowery our new study on attributes of T cells that contribute to successful cell therapy in cancer patients in @ScienceMagazine today w/ colleagues @slgoff_SB, @NCI_CCR_SB@theNCI a TL;DR thread on key findings with caveats :) 1/10 science.sciencemag.org/content/370/65…@NCI_CCR_SB has a long history of using tumor infiltrating T cells (TILs) to treat cancers since well.. before I was even born. We analyzed our most successful melanoma ACT trial for cell surface phenotypes in TIL infusion products of patients (aPD1/immunotherapy naive) /2
